Drug
Ipilimumab N01 clinical trials
- studies test it
- 6
- open now
- 6
- in phase 3
- 1
- first study started
- 2026
Keep track of what changes. Save the ipilimumab N01 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 5
Fudan University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Sun Yat-sen University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)
Often tested with
Tested in the same studies.
Sintilimab (6) · Bevacizumab (1) · Cetuximab (1) · Dabrafenib (1)
Studies
Open first, then newest update. How each study uses ipilimumab N01 is read from its arms, and is right about nine times in ten.
Testing it · 6
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Written as Ipilimumab N01
- A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingPhase 2Fudan UniversityNCT07878221Written as Ipilimumab N01
- Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2/3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07643623Written as Ipilimumab N01
- Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07560488Written as ipilimumab N01
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07506109Written as Ipilimumab N01
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07487662Written as ipilimumab N01